Context Therapeutics Inc. CNTX
0.35
(0.02)
(5.41%)
as of 25 Sep
- Market cap
- $34.1M
- P/E
- 0.0×
Follow CNTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
13.10 | 8.52 | 8.96 | 5.81 |
Net Debt/EBITDA |
7.25 | 4.78 | 5.84 | 2.87 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.69 | 1.32 | 0.48 | |
Capex/Depreciation |
0.00 | 0.00 | (7.94) | (2.79) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.07) | (0.09) | (0.12) | (0.07) | |
Cash per Share |
0.81 | 0.69 | 0.57 | 0.45 | |
Shareholders Equity per Share |
0.77 | 0.64 | 0.55 | 0.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.77 | 0.64 | 0.55 | 0.40 | |
Free Cash Flow |
(6.58) | (8.94) | (11.47) | (7.04) | |
Working Capital |
73.02 | 60.33 | 51.98 | 37.93 | |
Capital Expenditures |
0.00 | 0.00 | (0.04) | (0.02) | |
Net Current Asset Value |
73.00 | 60.33 | 51.86 | 37.86 | |
| Other line items | |||||
Quick Ratio |
12.75 | 8.23 | 8.35 | 5.45 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.09) | (0.12) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.87 | 1.99 | 1.73 | 2.84 | |
Average Assets |
82.78 | 83.31 | 75.91 | 66.64 | |
Average Common Equity |
78.52 | 77.87 | 71.59 | 60.36 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates